Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBatm Advanced Regulatory News (BVC)

Share Price Information for Batm Advanced (BVC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 19.65
Bid: 18.40
Ask: 19.65
Change: 0.00 (0.00%)
Spread: 1.25 (6.793%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 19.65
BVC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Annual Financial Report - DTR 6.3.5 Disclosure

30 Apr 2020 16:33

RNS Number : 5521L
BATM Advanced Communications Ld
30 April 2020
 

LEI: 213800FLQUB9J289RU66

30 April 2020

BATM Advanced Communications Limited

("BATM", the "Group" or the "Company")

ANNUAL FINANCIAL REPORT - DTR 6.3.5 Disclosure

Following the release on 4 March 2020 of the Group's Preliminary Results Announcement for the financial year ended 31 December 2019 (the "Preliminary Announcement"), BATM announces that the 2019 Annual Report and Accounts have been published today. These documents have been made publicly available on the BATM website (www.batm.com). The annual report can be found in the Investor Relations section under Financial Reports. The direct link is http://www.batm.com/investor-relations/financial-statements/.

In compliance with 9.6.1 of the Listing Rules, a copy of the 2019 Annual Report and Accounts will shortly be available for inspection at the FCA's National Storage Mechanism website: http://www.morningstar.co.uk/uk/NSM.

The primary purpose of this announcement is to inform the market about the publication of the Company's Annual Report and Accounts for the year ended 31 December 2019 (the "2019 Annual Report and Accounts").

The information below, which is extracted from the 2019 Annual Report and Accounts, is included solely for the purpose of complying with DTR 6.3.5 and the requirements it imposes on issuers as to how to make public annual financial reports. It should be read in conjunction with the Group's Preliminary Announcement. Together these constitute the material required by DTR 6.3.4 to be communicated to the media in unedited full text through a Regulatory Information Service. This material is not a substitute for reading the full 2019 Annual Report and Accounts. References to page numbers and notes to the accounts set out in the Appendices below refer to page numbers and notes to the accounts in the Group's 2019 Annual Report and Accounts.

The Preliminary Announcement includes an indication of the important events that occurred during the year and a condensed set of the financial statements.

The Group's auditor has reported on the accounts and its reports are unqualified. The Independent Auditor's Report on the Group financial statements is set out in full on pages 52-55 of the 2019 Annual Report and Accounts.

APPENDIX A - DIRECTORS' RESPONSIBILITY STATEMENT

The 2019 Annual Report and Accounts contain a responsibility statement in compliance with paragraph 4.1.12 of the DTR. The directors' responsibility statement is set out on pages 26-27 of the 2019 Annual Report and Accounts for the Group. This statement is set out below in full and unedited text.

The Directors are responsible for preparing the Annual Report, the Directors' Remuneration Report and the financial statements in accordance with applicable laws and regulations. The Directors are required to prepare financial statements for the Group in accordance with International Financial Reporting Standards as issued by the International accounting standard Board (IFRS). Israeli company law requires the Directors to prepare and approve such financial statements.

International Accounting Standard 1 requires that financial statements present fairly for each financial year the Company's financial position, financial performance and cash flows. This requires the faithful representation of the effects of transactions, other events and conditions in accordance with the definitions and recognition criteria for assets, liabilities, income and expenses set out in the International Accounting Standards Board's 'Framework for the Preparation and Presentation of Financial Statements'. In virtually all circumstances, a true and fair presentation will be achieved by compliance with all applicable International Financial Reporting Standards.

Directors are also required to:

properly select and apply accounting policies;

present information, including accounting policies, in a manner that provides relevant, reliable, comparable and understandable information;

make an assessment of the Company's ability to continue as a going concern and disclose where they consider it appropriate; and

provide additional disclosures when compliance with the specific requirements in IFRS is insufficient to enable users to understand the impact of particular transactions, other events and conditions on the entity's financial position and financial performance.

 

The Directors are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the Company, for safeguarding the assets, for taking reasonable steps for the prevention and detection of fraud and other irregularities and for the preparation of a Directors' Report and Directors' Remuneration Report which comply with the Listing Rules and the Disclosure and Transparency rules.

Legislation in Israel governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

Each of the Directors confirms to the best of his or her knowledge:

1. the financial statements, prepared in accordance with International Financial Reporting Standards, give a true and fair view of the assets, liabilities, financial position and profit or loss of the Company and the undertakings included in the consolidation taken as a whole;

2. the strategic report includes a fair review of the development and performance of the business and the position of the Company and the undertakings included in the consolidation taken as a whole, together with a description of the principal risks and uncertainties they face; and

3. the annual report and financial statements, taken as a whole, are fair, balanced, and understandable, and provide the information necessary for shareholders to assess the Company's position, performance, business model and strategy.

APPENDIX B - RISKS AND UNCERTAINTIES

The principal risks and uncertainties are set out on page 13 of the 2019 Annual Report and Accounts. The full and unedited text relating to these disclosures are set out below:

As the Group is involved in the development of new products and services, it is subject to the development risk inherent in such activity, including in particular the failure of products and services in development to proceed to completion and to the market. This includes the risk of failing key research and development hurdles such as clinical trials and regulatory authorisation.

The Group has made several acquisitions. Such growth in the Group carries increased demand for cash and resources in the Group's business, not all of which may be capable of being adequately serviced. Furthermore, certain acquisitions have not reached one hundred per cent ownership of the relevant target companies, in some cases due to local regulatory requirements as to share ownership and structuring. As a result, certain companies in the Group have non-controlling interests, typically held by the local management of the subsidiaries. Relationships with these non-controlling interests are frequently key to the continued success of the relevant business and projects. They carry certain risks, including those inherent in diversified control in a trading business, for example that key business decisions favoured by the Group may not proceed to implementation, and the consequences of a breakdown of the cooperation between the Group as the majority holder and the local partner as the minority.

The Group's diversified business activities include some, particularly within the Eco-Med and Distribution units, that are aimed at emerging markets, which have significant upward potential, yet at the same time are subject to greater risks than more developed markets, including economic, currency, political, social, legal and legislative risks. The Group's business and, consequently, its financial results and returns to investors may be adversely affected by a decrease in demand in such emerging markets, which can typically be less easy to predict or manage than in more stable and developed economies. The political and socioeconomic stability of emerging markets is frequently lower than that seen in more established markets, and this carries the risk that the Group's business and, consequently, its financial results and returns to investors may be adversely affected by negative changes in conditions for business and investment, which may occur more frequently or with more severity than in more developed markets. BATM has exposure to material fluctuations in currencies since BATM sells in various different currency zones including US Dollar, Euro, Romanian Lei and Moldavian Lei.

The World Health Organization declared COVID-19 a global emergency on 30 January 2020 with a significant number of countries declaring lockdown measures. The length and extent of the economic disruption caused by the outbreak is highly uncertain and cannot be predicted. The Group's Bio-Medical division was awarded a significant contract as a result of the crisis, but there can be no assurances that this will be repeated. Accordingly, the financial impact on the Group cannot be estimated at this time.

 

- Ends -

 

 

Enquiries

 

BATM Advanced Communications

Dr Zvi Marom, Chief Executive Officer

+972 9866 2525

Moti Nagar, Chief Financial Officer

Shore Capital

Mark Percy, Anita Ghanekar, James Thomas (Corporate Advisory)

Henry Willcocks (Corporate Broking)

+44 20 7408 4050 

Luther Pendragon

Harry Chathli, Claire Norbury, Rachel So

+44 20 7618 9100

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
ACSFLFVESLIIVII
Date   Source Headline
26th Nov 202012:21 pmRNSBlock Listing Interim Review
23rd Nov 202011:58 amRNSNotice of AGM
5th Oct 20207:00 amRNSMajor new customer for COVID-19 diagnostic tests
27th Aug 20207:00 amRNSBATM secures first tier 1 customer for NFVTime
17th Aug 20207:00 amRNSInterim Results
6th Aug 20206:16 pmRNSHolding(s) in Company
6th Aug 20207:00 amRNSNotice of Results
5th Aug 20208:09 amRNSSuccessful proof-of-concept with Vodafone
15th Jul 20207:00 amRNSBATM expands COVID-19 diagnostic tests
25th Jun 20207:00 amRNSBusiness and Trading Update
4th Jun 202012:01 pmRNSHolding(s) in Company
26th May 20207:00 amRNSBlock Listing Application
6th May 202011:45 amRNSHolding(s) in Company
5th May 20207:00 amRNSBATM Launches Antibody Tests for COVID-19
30th Apr 20204:33 pmRNSAnnual Financial Report - DTR 6.3.5 Disclosure
30th Apr 20207:00 amRNSCOVID-19 Update
22nd Apr 20207:00 amRNSBATM receives c. $31m order to produce ventilators
19th Mar 20207:00 amRNSNovamed partnership for COVID-19 diagnostics kit
6th Mar 20207:00 amRNSHolding(s) in Company
4th Mar 20207:00 amRNSFull Year Results
27th Feb 20207:00 amRNSBATM Develops Diagnostics Kit for COVID-19
24th Feb 20207:00 amRNSAward of $4m follow-on cyber contract
12th Feb 20207:00 amRNSNotice of Results
10th Feb 20207:00 amRNSThird international agri-waste contract
7th Feb 20207:00 amRNSHolding(s) in Company
23rd Jan 202011:43 amRNSHolding(s) in Company
22nd Jan 20205:54 pmRNSHolding(s) in Company
7th Jan 20207:00 amRNSFirst commercial agreement for Ador
5th Dec 20193:49 pmRNSResult of AGM
5th Dec 20197:00 amRNS$4m agri-waste treatment contract in Taiwan
7th Nov 20197:00 amRNSNotice of AGM
8th Oct 20197:00 amRNSDirector Share Purchases
7th Oct 20197:00 amRNSExpansion of cyber offering and follow-on contract
2nd Oct 20197:00 amRNSBATM completes delivery under Arm agreement
10th Sep 20197:00 amRNSDirector Shareholding, Issue of Equity and TVR
2nd Sep 20192:19 pmRNSHolding(s) in Company
23rd Aug 20197:00 amRNSBATM joins Tel-Aviv Stock Exchange indices
20th Aug 20192:34 pmRNSHolding(s) in Company
19th Aug 20197:00 amRNSInterim Results
7th Aug 201911:11 amRNSShare Option Exercise, Issue of Equity and TVR
5th Aug 20197:00 amRNSNotice of Results
31st Jul 20192:45 pmRNSReceipt of c. $3.4m from sale of IBC holding
22nd Jul 20197:00 amRNSBATM Advances 5G Strategy with New T-Metro 8104
11th Jul 20199:20 amRNSFirst Day Dealings on the Tel Aviv Stock Exchange
11th Jul 20197:45 amRNSFirst Day Dealings on the Tel Aviv Stock Exchange
8th Jul 20197:00 amRNSSecondary Listing on the Tel Aviv Stock Exchange
25th Jun 20198:28 amRNSResults of Placing and Subscription
24th Jun 20195:26 pmRNSProposed Fundraise to raise a minimum of US$15m
17th Jun 20197:00 amRNSNew solution under NXP Semiconductors partnership
10th Jun 20197:00 amRNSBATM Cyber Security Partnership with Clavister

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.